D. Boral Capital Reaffirms “Buy” Rating for OS Therapies (NYSEAMERICAN:OSTX)

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $20.00 target price on the stock.

OS Therapies Stock Up 2.9%

NYSEAMERICAN OSTX opened at $1.41 on Friday. OS Therapies has a 52 week low of $1.12 and a 52 week high of $2.57. The firm has a market capitalization of $49.65 million, a P/E ratio of -1.72 and a beta of -3.80. The company has a 50-day moving average price of $1.40 and a 200-day moving average price of $1.67.

Institutional Investors Weigh In On OS Therapies

A number of hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP bought a new position in OS Therapies in the 3rd quarter worth $29,000. Jane Street Group LLC purchased a new stake in OS Therapies in the fourth quarter worth about $39,000. Ground Swell Capital LLC bought a new position in shares of OS Therapies in the third quarter worth about $40,000. Mercer Global Advisors Inc. ADV bought a new position in shares of OS Therapies in the third quarter worth about $40,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of OS Therapies during the 2nd quarter valued at about $47,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.